Heart drug trial pulled before it even started
NCT ID NCT04306237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a planned Phase 2 study to test whether the drug IMB-1018972 could safely help people with refractory angina—chest pain that doesn't improve with standard treatments. The study aimed to measure exercise capacity, angina symptoms, and activity levels. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMB-1018972
- What this could lead to
- If it worked, this drug could improve exercise ability and reduce chest pain for people with refractory angina.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. Even if tested, it was an early Phase 2 study with uncertain benefits and potential side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ANGINA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imbria Investigational Site
Boston, Massachusetts, 02110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Hourglass-Shaped device relieve chest pain when arteries Aren't blocked?
- New heart device shows promise for angina sufferers
- Could your own bone marrow ease incurable chest pain?
- Could your own stem cells ease incurable chest pain?
- Implantable device could offer new hope for patients with untreatable chest pain